Keystone Symposia: Harnessing the Microbiome for Disease Prevention and Therapy
2021-01-18 - 2021-01-20 | VIRTUAL EVENT
Joint meeting with: The Microbiome: From Mother to Child
January 18-20, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET*
Our understanding of the microbiome is advancing rapidly, and continues to productively move through the discovery phase, with numerous correlations being established between specific commensal microbes or microbiota compositions and a wide range of diseases that includes infections, inflammatory conditions, metabolic disease, autoimmunity and neurologic syndromes. The initial discovery of these potentially important correlations has led many laboratories around the world to probe the molecular mechanisms that form the causal link between specific commensal microbes and disease development, progression and resolution. Although there have been great advances, culturing many of the prevalent and metabolically active obligate anaerobic commensals remains a challenge. Exciting advances, however, are emerging from laboratories developing tools to genetically manipulate key commensal organisms, facilitating experimental studies that are identifying the small, bioactive molecules they produce, some of which have therapeutic potential. Studies of the impact of bacteriophage on the microbiota also suggest that they may have therapeutic potential. This Keystone conference will focus on recent advances that demonstrate, at the cellular and molecular level, the impact of the microbiota and its products on disease susceptibility/resistance, with an emphasis on microbial and host metabolism, inter-microbial interactions and the amelioration of diseases.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Innovative Medicines Initiative (IMI) ENABLE Annual Meeting
2021-01-21 | VIRTUAL EVENT
Antimicrobial resistance (AMR) is a major public health threat. Infections caused by resistant bacteria are increasing and causing Europe to face soaring costs both in terms of lives and public health expenditure. Despite the strong need for new antimicrobials, very few new, effective antibiotics have been brought to the market in the last decades. The ENABLE project, within IMI’s New Drugs for Bad Bugs (ND4BB) programme, is working to advance the development of potential antibiotics against Gram-negative bacteria, such as Escherichia coli. The ultimate goal of the project is to develop attractive antimicrobial candidates for testing in the clinic, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients.
CARB-X participants include Erin Duffy, Chief of R&D.
Click here to learn more.

4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference
2021-01-26 - 2021-01-28 | VIRTUAL EVENT
Please make plans to join us for this outstanding line-up of internationally-renowned experts in antimicrobial resistance and stewardship.
Click here to learn more.
Click here to view the agenda.
Click here to register.

5th Microbiome Movement - Drug Development Summit Europe 2021
2021-01-27 - 2021-01-29
Participants include CARB-X funded companies Eligo Bioscience and Seres Therapeutics.
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.
Part of the foremost conference series for microbiome researchers in industry, the 5th Microbiome Movement – Drug Development Europe 2021 will return to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.
To learn more, click here.
To view the program, click here.
To register, click here.

BSAC/GARDP Antimicrobial Chemotherapy Virtual Conference 2021
2021-02-02 - 2021-02-03 | VIRTUAL EVENT
Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators are the Helmholtz Institute for Pharmaceutical Sciences (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)
Click here to learn more.
Click here to register.

C-CAMP AMR Webinar Series: Pre-Clinical and Early Drug Development in India
2021-02-02 10:00 - 12:00 (America/New_York) | VIRTUAL EVENT
India is fast emerging as one of the global hubs for conducting pre- clinical and clinical development. The webinar will showcase the competencies of some of the CROs
in India and how Product Developers can leverage the advantages of working with Indian CROs.
Participating CROs include:

Bioneeds India
Syngene International
SIRO Clinpharm
Sai Life Sciences
GVK Bio

Click here to learn more and register.
Click here to view the zoom link.

The Bloomsbury SET Conference on Infectious Disease and AMR
2021-02-22 - 2021-02-26 | VIRTUAL EVENT
The Bloomsbury SET is hosting its first virtual conference focused on knowledge exchange and infectious disease during the 22nd to 26th February 2021.
Throughout the week, the Bloomsbury SET and wider partners will explore interdisciplinary innovation, research translation, commercialisation, impact and connecting capabilities to tackle global health challenges through knowledge exchange.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Phage Futures Congress
2021-02-24 - 2021-02-26 | VIRTUAL EVENT
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond. Discover how you can be at the forefront of the developing phage therapy market. Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies.
Among other topics, expect to hear & participate in:

Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.
Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.
Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.
Expert advice on how to find & secure financial investments.

CARB-X participants include Richard Alm, Alliance Director.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Live Webinar: GARDP/REVIVE – From discovery to IND: Roadmap to a successful antibacterial project
2021-02-25 11:00 - 12:30 (America/New_York)
Speakers: Patricia Bradford, Antimicrobial Development Specialists LLC (US); Alita Miller, Entasis Therapeutics (US)
Moderator: Michael Mourez, École d’Ingénieurs de PURPAN (France)
The presentations will be followed by a Q&A session.
Click here to learn more and register.

Live Webinar: GARDP/REVIVE – Learning from COVID-19 to tackle the silent pandemic of antibiotic resistance
2021-03-04 10:00 - 11:30 (America/New_York) | VIRTUAL EVENT
The COVID-19 pandemic has brought into sharp focus the impact of pandemics. The novel coronavirus has claimed more than a million lives, trillions of dollars have been lost, expenditures cut and international efforts to achieve the Sustainable Development Goals put in jeopardy.
COVID-19 has demonstrated pandemic preparedness requires a global coordinated effort, and no country can do it alone. Strengthening our ability to fight the silent pandemic of drug-resistant infections must also ensure affordable access to vital health tools, including new and improved treatments. This webinar will focus on how we can apply the lessons learned from COVID-19 to tackle drug resistance and ensure access to appropriate antibiotics.
Speakers:

Manica Balasegaram, GARDP
Joanne Liu, University of Montreal and Médecins Sans Frontières
Marc Mendelson, Groote Schuur Hospital, University of Cape Town

Moderator: Claire Doole
The presentations will be followed by a Q&A session.
Click here to learn more and register.

BARDA AMR Vaccine Public Workshop: Vaccines against AMR Threats
2021-03-12 11:00 - 13:00 (America/New_York) | VIRTUAL EVENT
Multi-drug resistant (MDR) organisms are a threat to national security and public health. As rates of antimicrobial resistance (AMR) in pathogens continue to increase new therapeutics and vaccines are essential to combat the growing crisis. Every year, 2.8 million American develop a drug resistant infection and 35,000 people die. Globally, MDR infections kill 700,000 each year – current estimates are that MDR organisms will kill more than 10 million a year by 2050 if left unchecked.
BARDA supports development and procurement of medical countermeasures to protect Americans against chemical, biological, radiological, and nuclear (CBRN) threats. MDR does not discriminate, and victims of CBRN events are at risk of suffering fatal complications from drug resistant infections. One of BARDA’s top priorities is to develop a vaccine to protect people from these threats.
Help BARDA fight AMR! Join the workshop to learn more about BARDA, our mission, and how we plan to tackle this growing threat. The event will consist of presentations from BARDA experts, followed by a structured discussion, and Q&A. Companies and others interested in working with BARDA are encouraged to attend the March 12, 2021 workshop. The event is open to the public, but space is limited. Be sure to register by March 5, 2021. Please, no more than four people from one organization. Are you a product developer working on a vaccine against one of the four targeted pathogens? Then we want to talk with you! Be sure to request a private meeting when you register for the workshop.
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more.
Click here to register.

3rd Bacteriophage Therapy Summit 2021
2021-03-23 - 2021-03-24 | VIRTUAL EVENT
The 3rd Bacteriophage Therapy Summit returns! With a new looking speaker line-up and never before seen content, we are excited to continue to unite the community to progress fundamental bacteriophage research into clinically-significant products.
The overuse of antibiotics had led to the development of multi-resistant bacterial strains, most notably ESKAPE pathogens, rendering the use of antibiotics, which in many scenarios are useless. However, bacteriophages may hold the key in overcoming the global antibiotic resistance crisis.
Although the potential use of phage and phage-derived products in a clinical setting is beginning to be understood, there still remains a number of unique challenges associated with this novel therapeutic agent. A developing regulatory landscape, up-scaling of manufacturing processes, and the design of clinical trials are just a few of the roadblocks holding back development.
Bringing together leading drug developers, academics and clinical researchers, our agenda is focused to address the main translation challenges from characterization of phages through to clinical development. This is your opportunity to join your peers to strengthen your product development pipelines and forge new collaborations to unlock the full potential of bacteriophage therapeutics.
CARB-X participants include Richard Alm, Alliance Director.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Australasian Society for Infectious Diseases (ASID) Annual Scientific Meeting
2021-03-24 - 2021-03-26 | Pullman Melbourne on the Park, 192 Wellington Parade, MELBOURNE, 3002, Australia
The ASID Annual Scientific Meeting is the leading Australasian meeting for adult and paediatric infectious disease and clinical microbiology specialists. The conference is an ideal opportunity for connecting clinicians, microbiologists and other health professions with a common interest in infectious diseases and provides a friendly forum for the exchange of scientific advances in the prevention, diagnosis and management of clinical infectious diseases. International speakers will offer expert global perspectives on our themes and Australasian research and expertise will be highlighted with keynote lectures, proffered papers and symposia. The main theme is “Hospital Infectious Diseases”
Click here to learn more.
Click here to view the agenda.
Click here to register.

The Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (Levy CIMAR) Monthly Science Meeting: Innovation Solutions to AMR
2021-03-25 12:00 - 13:00 (America/New_York) | VIRTUAL EVENT
Please join us on Thursday, March 25th, at noon for this month’s Levy CIMAR Science Meeting on “Innovation Solutions to AMR.” We are excited to hear from Kevin Outterson, Esq., Professor of Law at Boston University and Executive Director of the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X. CARB-X is a global partnership hosted at BU Law that is focused on supporting developers of promising new antibiotics, diagnostics, and vaccines that tackle the threat of untreatable bacterial infections.
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more about Levy CIMAR.
Contact Rima Mycynek @ Rima.Mycynek@tufts.edu for Zoom Details.

Decennial Day: 6th International Conference on Healthcare Associated Infections
2021-04-12
We are excited to announce ‘Decennial Day’ which will be a complimentary program to SHEA Spring 2021. Decennial Day will feature a few selected sessions from the 2020 Decennial Program to be virtually held on April 12, 2021. More information to come on sessions and speakers at a later date.
You will automatically be registered for Decennial Day when you register for SHEA Spring 2021. If you wish to only sign up for Decennial Day (and not SHEA Spring) you may do so. Learn More
CARB-X participants include Kevin Outterson, Executive Director.
Click here to learn more.
Click here to view the agenda.
Click here to register.

SHEA Spring 2021 Conference
2021-04-13 - 2021-04-16 | VIRTUAL EVENT
Who should come to SHEA Spring 2021?
SHEA members and non-members of all disciplines relating to Infection Prevention Programs, Antibiotic Stewardship Programs, Public Health, Pharmacy, Occupational Health, Clinical Microbiology, Quality Improvement, and Patient Safety. If you are involved in infection prevention or infection control you need to be at SHEA Spring 2021!
Click here to learn more.
Click here to view the agenda.
Click here to register.

Anti-Infectives Drug Development Summit
2021-04-20 - 2021-04-22 | VIRTUAL EVENT
Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
CARB-X participants include Kevin Outterson, Executive Director, who will be leading the session “Surviving FDA Approval of your Antibiotic” on Wednesday April 21 at 9:25am ET / 6:25am PDT. He will touch upon:

What can we learn from the past decade of FDA antibiotic approvals? •
Niche markets where your drug can differentiate from generics
Non-dilutive funding: CARB-X, BARDA, HERA
Exit: AMR Action Fund, PASTEUR

CARB-X funded companies participating include Peptilogics, Vedanta, Antabio, Bioversys, ContraFect, Locus, Techulon, Summit, and MicuRx.
Click here to learn more.
Click here to view the event guide.
Click here to register.

JPIAMR Therapeutics Workshop - Feeding the Antimicrobial Pipeline
2021-04-20 - 2021-04-22
As AMR emerges, new strategies for the treatment of infection and identification of resistant microbes are crucial. This JPIAMR activity, led by the UK Medical Research Council (MRC) with support from South Africa (SAMRC), Korea (NRF), France (ANR), and Canada (CIHR) is delivered as part of JPIAMR’s mission to enable global coordination of research.
The workshop “Feeding the AMR Therapeutics Pipeline” will bring together academics, industry, innovators, and policymakers to discuss the global antimicrobial development pipeline, identify gaps and opportunities for future research and development, and support collaboration for creative solutions to real-world problems facing therapeutics development in the context of antimicrobial resistance (AMR).
The workshop is organised online in three half-day sessions, (13:00-17:00 CET) from the 20th to the 22nd of April 2021, combining keynote presentations, short invited talks selected from abstract submissions, and panel discussions.
CARB-X participants include Kevin Outterson, Executive Director, who will be leading session “Session 2 Choosing wisely – is your product worth developing?” which will take place between 14:50 to 15:50 CET on April 20th.
Click here to learn more.
Click here to register.

Anti-Infectives Drug Development Summit
2021-04-20 - 2021-04-22 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments, biopharma, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance.
With some now considering the field as the new ‘Wall Street darling’, especially given the $1 billion launch of the AMR action fund, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs.
Bringing together 60+ senior leaders from large pharma, innovative biotech, academia and investment companies, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates, novel modalities and effective strategies, that address market sustainability and aim for superiority.
Here is a sneak peak of the world-class speaker faculty:

Cara Cassino, Executive Vice President of R&D & Chief Medical Officer, ContraFect
Kevin Outterson, Executive Director, CARB-X
Silas Holland, Head of External Affairs (Interim) & Director of Global Policy, Merck & The AMR Action Fund
David Powell, Chief Scientific Officer, Summit Therapeutics
Dave Ousterout, Chief Scientific Officer, Locus Biosciences
Angela Talley, Vice President of Clinical Development, Spero Therapeutics
Ercem Atillasoy, Chief Regulatory & Safety Officer, AlloVir
David Alterac, Chief Medical Officer, Entasis Therapeutics

Click here to learn more.
Click here to view the agenda.
Click here to register.

Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea; Public Workshop
2021-04-23 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
FDA, NIAID and CDC are announcing a public workshop regarding the development considerations of antimicrobial drugs for the treatment of gonorrhea. The workshop will focus on the current state and nonclinical and clinical trial design considerations regarding antimicrobial drug development for gonorrhea and include the following topic areas:

Animal models
Clinical pharmacology considerations
Trial design considerations for gonorrhea, such as enrollment strategies, choice of comparators and site of infection.

This meeting will be held in virtual format only. Registration is required for online attendance.
To learn more, click here.
Additional details forthcoming.

9th Annual Cystic Fibrosis Symposium 2021
2021-04-24 08:00 - 12:30 (America/Los_Angeles) | Auditorium at UCLA Medical Center, Santa Monica, 1250 16th Street, Santa Monica, CA, 90404, United States
This course is designed to increase the knowledge of managing patients with CF across the lifespan of all who interact with this population.
About this Event
The target audience includes nurses, respiratory therapists, physical and occupational therapists, social workers, dieticians, child life specialists, and physicians
Click here to learn more and register.

BactiVac Online: Virtual Network Conference 2021
2021-04-27 - 2021-04-28 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
Delivering our 2021 Virtual Network Conference in an innovative online format will provide a unique opportunity to hear about the latest bacterial vaccinology research from leading international researchers in a safe environment. Talks will be delivered by a host of internationally renowned speakers from a range of disciplines, all actively involved in the research area of bacterial vaccinology. Please view the programme for our virtual conference, together with speaker profiles.
The conference is open and free to attend for BactiVac Network members only and booking is compulsory; you can apply for free membership here. Registration for the conference is now closed.
Keep up to date by following us on @BactiVac, using #BactiVacEvents. You can also download BactiVac Virtual Conference flyer to circulate and/or display within your organisation.
For any queries regarding virtual conference, please contact us at: bactivac@contacts.bham.ac.uk
Click here to learn more.

BSAC Spring Conference
2021-04-29 - 2021-04-30
Additional details forthcoming. Click here to learn more.

Live Webinar: GARDP/REVIVE – AMR R&D efforts in the CMC and formulation arena: Do it right the first time!
2021-04-29 11:00 - 12:30 (America/New_York) | Webinar
Speaker: Aleksandar Danilovski, Chief Scientific Officer, Xellia Pharmaceuticals (Denmark)
Moderator: TBC
Aleksandar’s presentation will discuss:

Are CMC and formulation efforts treated as the foster child in the innovation and development armament?
Underestimating CMC and formulation aspects can potentially cause significant delays and project failures
Appropriate (what, how and when) CMC and formulation innovation and development strategies can improve overall probability of project success, can bring competitive advantages (including IP umbrella) and can reduce time to market – Do it right the first time!

The presentation will be followed by a Q&A session.
Click here to learn more and register.

World Vaccine Congress Washington 2021
2021-05-04 - 2021-05-06 | VIRTUAL EVENT
For the past 20 years, the World Vaccine Congress Washington congress has evolved and grown into the leading vaccines congress globally, with hundreds of speakers, thousands of attendees and hundreds of networking opportunities. Our event format allows for whole-sector topics, giving an opportunity for people to find out more about their specific area of research and their job-function. By running parallel niche conference channels over the 3 days, it increases the relevance of the whole event for everyone who attends.

Cancer Immunotherapy
Immune Profiling
Respiratory Vaccines
Emerging & Infectious Diseases
Clinical Trials
Vaccine Partnerships
Bioprocessing & Manufacturing
Vaccines Safety
Logistics
Veterinary Vaccines
Partnerships

During these sessions you will learn how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce more and better vaccines to the market.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Duke-Margolis Center for Health Policy Webinar: Combating Rising Antimicrobial Resistance (AMR) & Advancing Public Health Preparedness
2021-05-12 11:00 - 12:30 (America/New_York) | WEBINAR, Webinar, Webinar, United States
Join the Duke-Margolis Center for Health Policy—including an introduction by former FDA Commissioners Dr. Mark McClellan and Dr. Scott Gottlieb—for an important discussion on combating rising antimicrobial resistance (AMR) in the context of U.S. public health preparedness, support for novel antibiotics, global AMR policy leadership, and emerging multi-sector innovation.
Rising antimicrobial resistance remains a top global public health threat and efforts to support novel antibiotic development and availability are more critical and timely than ever. As the ongoing pandemic centers national and global conversations around actions to prevent and combat future infectious disease threats, the time to take action against AMR is now.
CARB-X participants include Kevin Outterson, Executive Director, who will join the panel for Session 2: Global Policy Leadership and Proposals to Combat AMR at 11:25AM ET. This session will highlight how the U.S. can lead policy approaches to combat AMR through existing legislative proposals and opportunities to coordinate domestic
actions with existing international efforts.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Gordon Research Conference: Structure, Dynamics and Development of Bacterial Cells
2021-06-20 - 2021-06-25 | Colby-Sawyer College, 541 Main Street, New London, NH, 03257, United States
Bacterial cells are exquisitely organized in time and space, and carry out complex decision-making, intercellular coordination, and development to thrive in diverse environments. The 2021 inaugural Bacterial Cell Biology and Development Gordon Research Conference will explore recent research into the organization, dynamics, and development of bacterial cells and communities using a breadth of experimental approaches and biological systems. Invited speakers will present work probing the fundamental cell biological mechanisms of growth and division, and of the specialized behaviors and developmental pathways bacteria engage to ensure survival in changing environments. Inclusion of research in species that span bacterial phylogeny, lifestyles, and growth niches will stimulate thought and discussions on the conservation and evolution of cell biological mechanisms in bacteria.
The 2021 Bacterial Cell Biology and Development GRC brings together a group of international scientists including cell biologists, bacteriologists, biochemists, geneticists, physicists, structural biologists, and imaging specialists to facilitate a collaborative and interdisciplinary discussion of bacterial cell biology and development. The program will comprise talks from 24 invited speakers organized into 9 thematic sessions, with an additional ~20 short talks selected from submitted abstracts. Daily poster sessions and ample free time will enable networking, collaboration, brainstorming, and other informal interactions among attendees. As a new GRC, we are not able to hold a trainee-oriented Gordon Research Seminar in conjunction with this inaugural meeting. Look for this offering in future iterations of this GRC.
Click here to learn more.
Click here to register.

World Microbe Forum
2021-06-20 - 2021-06-24 | Virtual Event, 765 Commonwealth Avenue, Boston, MA, 02215, United States
From new infectious pathogens like SARS-CoV-2, to antimicrobial resistance and the role of microbes in climate change, to agriculture and food microbiology, and synthetic and applied microbiology – international experts will gather for World Microbe Forum to examine, discuss and envision solutions that science can offer to solve some of the gravest concerns confronting us today.
This unique and special event, a collaboration between the American Society for Microbiology (ASM) and the Federation of European Microbiological Societies (FEMS), is bringing together two of the biggest events in the microbial sciences, ASM Microbe 2021 and FEMS2021, to further science and help answer some of the most important questions impacting humankind. Additional scientific societies, including the American Society for Virology (ASV) and the African Society for Laboratory Medicine (ASLM) will be key partners in this event.
Explore the hottest topics in microbiology, discussed like never before, and offering unparalleled access to the latest innovative research across global perspectives. Create meaningful connections with peers from around the world. Be a part of this first-of-its-kind virtual meeting uniting the microbial sciences community.
CARB-X participants include Erin Duffy, Chief of R&D, who will join a panel focused on “Advancing Collaborations in the Global Fight Against AMR and Pandemics” on June 21st from 11am to 12:30pm ET.
Click here to learn more.
Click here to view the agenda.
Click here to register.

Sepsis Tech & Innovation 2021
2021-06-22 - 2021-06-23 | VIRTUAL EVENT
Following the success of the inaugural Sepsis Alliance Summit in 2020, Sepsis Alliance is proud to announce the inaugural Sepsis Tech & Innovation virtual conference. Engage with the nation’s leading innovators, clinicians, investors, and policymakers to discuss health technology and innovation, and its tremendous potential to reduce the burden of sepsis.
Catapulting off of Sepsis Alliance’s successful 2020 Sepsis Alliance Summit with more than 4,000 registered attendees, Sepsis Tech and Innovation is a very exciting opportunity for Sepsis Alliance to expand its voice in the health innovation and technology space. Our ultimate goal is to help take the costly guesswork out of sepsis diagnosis and care. In addition to education and training, technology and innovation are critical to achieving major progress in reducing the burden of sepsis, both in terms of lives lost and resources spent. Sepsis may be the best opportunity to leverage tech and innovation to save lives and reduce health spending in the nation. Sepsis Alliance is proud to offer Sepsis Tech & Innovation at no charge to participants.
CARB-X participants include Erin Duffy, Chief of Research and Development, who will be leading the session “Therapeutics: Innovation and Challenges in the Fight Against AMR” on June 23, 12:40pm – 1:10pm ET.
Click here to learn more.
Click here to register.

Promoting Innovative Antibiotic R&D in Switzerland
2021-06-24 | Ort Hotel ODELYA, Missionstr. 21, Basel, CH-4055, Switzerland
The event “Promoting Innovative Antibiotic R&D in Switzerland” brings together protagonists of Antibiotic Research and Development from academic, industrial, political and funding organizations active in Switzerland.
Its objective is discussing ways to facilitate technology transfer from academia to an industrial setting and to further the development of an attractive ecosystem, at national and international level, for bringing new antibiotics to the market.
Initially planned for March 2020 and postponed due to COVID-19, this gathering of the Antibiotic R&D community is all the more anticipated to give impulses to the field on 24th June 2021!
June 24th, 2021 l Ort Hotel ODELYA, Missionstr. 21, CH-4055 Basel
Click here to learn more.
Click here to view the agenda.
Click here to register.
